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Summary
Background: Normal stress myocardial perfusion images (MPI) generally show good prognosis
for cardiovascular events. However, chronic kidney disease (CKD) is one of the important risk
factors for coronary artery disease (CAD), and the interpretation of normal stress MPI has not
been well established in CKD patients with no evidence of CAD. The purpose of this study was
to evaluate the long-term prognostic value of stress MPI in CKD patients with no evidence of
myocardial ischemia or infarction.
Methods: Patients who had no history but were suspected of CAD and had normal stress MPI
(n = 307, male = 208, age = 67 years, CKD/non-CKD = 46/261) were followed-up for 4.5 years. CKD
was deﬁned as a glomerular ﬁltration ratio of <60ml/min/1.73m2 and/or persistent proteinuria.
Cardiac death, non-fatal myocardial infarction, and unstable angina requiring hospitalization
were deﬁned as major cardiac events.
Results: Major cardiac events were observed in 3 of 261 (1.1%) non-CKD patients and 6 of 46
(13%) CKD patients (p < 0.001, with log-rank test). CKD was an independent risk factor for major
cardiac events (hazard ratio = 13.1, p < 0.001, multivariate Cox regression analysis).
Conclusions: Normal stress MPI does not always promise a good prognosis for major cardiac
events. Even in patients with no evidence of CAD from stress MPI, CKD can be an independent
and signiﬁcant risk factor for m
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ormal ﬁndings on stress myocardial perfusion images (MPI)
enerally predict a low risk for cardiac death and acute coro-
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nary syndrome, with an annual event rate of less than 1%
[1—7]. Even in patients with risk factors such as a history
of coronary artery disease (CAD), diabetes mellitus, or both
conditions, normal stress MPI predicts a good prognosis, with
an annual event rate of less than 1.8%, which is only slightly
higher than that in patients without either diabetes or CAD
[8—12]. The association between chronic kidney disease
(CKD) and adverse cardiovascular prognosis has been well
established from large community-based studies [13—16].
This association has been observed in patients with a his-
tory of myocardial infarction (MI) [17—19] and congestive
heart failure [19—21], as well as after coronary artery bypass
grafting surgery [22,23], or percutaneous coronary interven-
tions [24,25]. However, between CKD and non-CKD patients,
the importance of stress MPI for patients with no evidence
of CAD is unclear.
In this study, we investigated differences in the occur-
rence of major cardiac events between CKD and non-CKD
patients who had no evidence of CAD.
Materials and methods
Patients and study protocol
Eight hundred and ﬁfty four consecutive patients suspected
of CAD underwent a thallium-201 stress MPI between 2003
and 2004 and were followed for a mean of 4.5 years. One
hundred and forty-two patients were not followed-up. Of
the remaining patients, 290 patients with abnormal stress
MPI, 65 patients with a history of CAD, and 50 hemodialysis
patients were excluded from this study. The remaining 307
patients with normal stress MPI were observed (Fig. 1). All
patients gave informed consent to participate in this study,
which was approved by the Committee on Human Investi-
gation of the Toho University Ohashi Medical Center and
performed in accordance with the ethical standards of the
1964 Declaration of Helsinki and all subsequent revisions.Exercise and pharmacological stress tests
Either treadmill exercise or pharmacological stress tests
were performed. Electrocardiographic and hemodynamic
monitoring was conducted, and symptom-related stress
(
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f
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Figure 1 Flow diagram of the study population.329
ests were recorded. The treadmill exercise test (Bruce
rotocol) was considered adequate if the patient reached
ore than 85% of the maximum predicted heart rate and/or
eveloped chest pain. Patients with a limited exercise
apacity, who failed to achieve at least 85% of their pre-
icted heart rate during the treadmill test, underwent a
harmacological stress test. The pharmacological stress test
as performed by intravenous infusion of adenosine triphos-
hate (ATP). One vein in each arm was used for ATP infusion
nd thallium-201 injection. An automatic infusion pump was
sed to deliver ATP (0.16mg/kg/min) over 6min. Thallium-
01 (111MBq) was injected into a peripheral vein about
min before the end of the treadmill stress test or 3min
fter the start of ATP infusion.
yocardial perfusion single photon emission
omputed tomography imaging
ll patients underwent stress myocardial perfusion imaging
ith thallium-201 (111MBq; Daiichi Radioisotope Labora-
ory, Tokyo, Japan) using a three-headed gamma camera
MS-3, Siemens, Chicago, IL, USA) equipped with a
ow-energy cardiofocal collimator and interfaced with a
omputer (ICON, Siemens). Stress single photon emission
omputed tomography (SPECT) imaging was performed
0min after the stress test, and rest SPECT imaging was
erformed 4 h after stress imaging. Ninety projections were
btained for 20 s each in 4◦ steps around a 360◦ circle. All
rojections were stored on 64× 64 matrices. A 15% symmet-
ical energy window centered on the 70-keV peak was used.
omographic reconstruction was performed by the standard
ltered back projection technique using a Butterworth ﬁlter
ith a cut-off frequency of 0.5 cycles/pixel and an order of
. There was no correction for attenuation or scatter. SPECT
mages were reoriented in the short, horizontal, and ver-
ical long axes for analysis. Presence of perfusion defects
as determined by agreement between two experienced
nterpreters without knowledge of patient identity or clin-
cal information, who classiﬁed the defects as reversible
including partially reversible) or ﬁxed (irreversible).
SPECT images were assessed in the following manner to
etermine the presence, location, and severity of any per-
usion abnormalities (Fig. 2). The left ventricle was divided
nto 17 segments, and each segment was assigned a score,
MPI indicates myocardial perfusion images.
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Figure 2 Single photon emission computed tomography
images were assessed to determine the presence, location,
and severity of defects. The left ventricle was divided into
17 segments and each segment was assigned a score, by
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Pgreement of the observers, using a ﬁve-point scoring sys-
em (0 = normal, 1 =mildly reduced, 2 =moderately reduced,
= severely reduced, and 4 = absent uptake).
y the agreement of more than two observers, using a
ve-point scoring system (0 = normal, 1 =mildly reduced,
=moderately reduced, 3 = severely reduced, and 4 = absent
ptake). The sum of the segment scores at stress (SSS),
cores at rest [summed rest score (SRS)], and differences
etween the stress and rest score [summed difference score
SDS)] were calculated. The score for each myocardial seg-
ent on the images was calculated, and a stress score ≤1 for
ach segment, SSS ≤3, and SDS ≤1 was considered normal
2,26,27].
The myocardial washout rate for thallium-201 was also
alculated for each patient.
lassiﬁcation of CKD
he estimated glomerular ﬁltration rate (eGFR) was calcu-
ated using the four-variable modiﬁed diet in renal disease
MDRD) equation [28]:
FR = 175 × [serum creatinine (mg/dl)]−1.154
×age−0.203 × 0.741 (Japanese) × 0.742 (if female)
GFR was obtained at a mean of 34± 20 days from
he time of myocardial perfusion imaging. CKD was
eﬁned by the National Kidney Foundation [29]; eGFR was
60ml/min/1.73m2 and/or persistent proteinuria more
han 3 months, and present in 46 patients (15%). CKD
atients were categorized into ﬁve eGFR stages: Stage I,
90ml/min/1.73m2 (n = 4); Stage II, 60—90ml/min/1.73m2
n = 1); Stage III, 30—60ml/min/1.73m2 (n = 29);
tage IV, 15—30ml/min/1.73m2 (n = 8); and Stage V,
15ml/min/1.73m2 (n = 4). Patients with acute renal fail-
re (deﬁned by an ≥0.5mg/dl increase in serum creatinine
n <2 weeks or increase of >20% over baseline if serum
reatinine was ≥2.5mg/dl) were excluded.chocardiography, clinical and laboratory data
eft ventricular end diastolic diameter (EDD), left ven-
ricular end systolic diameter (ESD), and left ventricular
T
s
C
oT. Furuhashi et al.
jection fraction (LVEF) were measured by M-mode echocar-
iography within 1 month of myocardial perfusion imaging.
e deﬁned diabetes on the basis of a glycosylated
emoglobin (HbA1c) level of >7.0% or current treatment
ith insulin or oral antidiabetic agents. Hypertension was
eﬁned as current antihypertensive therapy, a systolic blood
ressure ≥140mmHg, and/or a diastolic blood pressure
90mmHg. Hypercholesterolemia was deﬁned as current
holesterol lowering therapy and/or a total cholesterol level
220mg/dl. Hypertriglyceridemia was deﬁned as current
riglyceride lowering therapy and/or a serum triglyceride
evel >150mg/dl. Patients with hyperlipidemia were deﬁned
s patients with hypercholesterolemia and/or hypertriglyc-
ridemia. Peripheral artery disease (PAD) was deﬁned from
revious medical history and/or ankle brachial index (ABI)
f less than 0.9 [30,31].
ndpoints and follow-up
ollow-up was initiated after assessment of cardiac function
nd performance of stress myocardial perfusion imaging.
he primary endpoint was cardiac death, which included
udden cardiac death, fatal MI, death due to heart fail-
re, or death due to arrhythmia. Sudden cardiac death was
eﬁned as a witnessed cardiac arrest or death within 1 h
fter the onset of acute symptoms or unexpected death
i.e. during sleep) in patients known to have been well for
he previous 24 h. The secondary endpoints were non-fatal
I and Braunwald class III unstable angina requiring hospi-
alization. Braunwald class III unstable angina was deﬁned
s acute angina at rest within 48 h of onset. Both primary
nd secondary endpoints were deﬁned as major cardiac
vents.
Patients were followed-up regularly for a mean of 4.5
ears (range, 2—72 months).
tatistical analysis
esults are presented as the mean± SD. The chi-square test
as used for comparing differences in gender, underlying
isease, and medical treatment between CKD and non-
KD patients. Student’s t-test was employed to compare
ge, body mass index, LVEF, and parameters of laboratory
ata and stress myocardial perfusion images. Cox regres-
ion hazard analysis was adopted to detect risk factors.
aplan—Meier event-free curves were drawn, and the log-
ank test was used to compare the risk of cardiac events
etween CKD and non-CKD patients. All analyses were per-
ormed with the SPSS statistical program package (SPSS II;
PSS Inc., Chicago, IL, USA), and a p-value < 0.05 was con-
idered to indicate signiﬁcance.
esults
atient proﬁleable 1 summarizes the baseline characteristics of the
ubjects. There were no signiﬁcant differences between
KD and non-CKD patients with respect to age, gender,
r body mass index. The frequency of hypertension, dia-
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Table 1 Patients’ characteristics.
Overall (n = 307) CKD (n = 46) Non-CKD (n = 261) p-Values
Age (years) 67± 10 67± 13 67± 10 n.s.
Male (n) 164 (53%) 24 (52%) 140 (54%) n.s.
Body mass index 23.7± 3.6 24.3± 4.5 23.5± 3.4 n.s.
>25 kg/m2 91 (30%) 14 (30%) 77 (30%) n.s.
Baseline disease
Hypertension 164 (53%) 36 (78%) 128 (49%) <0.001
Diabetes 73 (24%) 19 (41%) 54 (21%) 0.004
Hyperlipidemia 123 (40%) 23 (50%) 100 (38%) n.s.
Hypercholesterolemia 42 (14%) 10 (22%) 32 (12%) n.s.
Hypertriglyceridemia 69 (22%) 16 (35%) 53 (20%) 0.010
Cerebral artery disease 25 (8%) 4 (9%) 21 (8%) n.s.
Peripheral artery disease 13 (4%) 2 (4%) 11 (4%) n.s.
Smoking 93 (30%) 22 (48%) 71 (27%) 0.008
Brinkman index 236± 529 317± 434 221± 543 n.s.
Familial history of CAD 91 (30%) 14 (30%) 77 (30%) n.s.
Echocardiography
EDD (mm) 48± 8.8 48± 9.0 50± 8.0 n.s.
ESD (mm) 33± 9.2 34± 6.5 33± 5.8 n.s.
LVEF (%) 66± 8.7 66± 7.2 66± 9.0 n.s.
<40% 1 (0.3%) 0 (0%) 1 (0.4%)
Number of risk factors
0 59 (19%) 5 (11%) 54 (21%)
1 118 (38%) 12 (26%) 106 (41%)
2 93 (30%) 15 (33%) 78 (30%) <0.001
3 32 (10%) 10 (22%) 22 (8%)
4 5 (2%) 1 (2%) 4 (2%)
5 0 (0%) 0 (0%) 0 (0%)
Laboratory data
Hemoglobin (g/dl) 13.4± 1.5 12.5± 2.0 13.6± 1.4 <0.001
Total protein (g/dl) 7.2± 0.6 7.0± 0.8 7.3± 0.5 0.007
Albumin (g/dl) 4.0± 0.4 3.8± 0.5 4.1± 0.3 <0.001
BUN (mg/dl) 17± 9.6 28± 20 15± 4.0 <0.001
Creatinine (mg/dl) 0.9± 0.6 1.8± 1.3 0.7± 0.2 <0.001
GFR (ml/min/1.73m2) 91± 28 47± 25 99± 21 <0.001
CRP (mg/dl) 0.09± 0.16 0.13± 0.18 0.09± 0.15 n.s.
HbA1c (%) 6.2± 1.5 6.6± 1.3 6.1± 1.5 n.s.
Total cholesterol (mg/dl) 204± 37 207± 47 204± 35 n.s.
HDL (mg/dl) 61± 18 54± 17 62± 17 0.003
LDL (mg/dl) 117± 33 126± 41 115± 32 0.046
LDL/HDL 2.11± 0.93 2.61± 1.21 2.01± 0.84 <0.001
Triglyceride (mg/dl) 130± 76 151± 75 126± 75 0.037
BNP (pg/ml) 101± 157 111± 83 100± 165 n.s.
Medications
ACE-I 24 (8%) 5 (11%) 19 (7%) n.s.
ARB 73 (24%) 22 (48%) 51 (20%) <0.001
Beta-blocker 47 (15%) 16 (35%) 31 (12%) <0.001
Ca channel blocker 124 (40%) 24 (52%) 100 (38%) n.s.
Nitrates 20 (7%) 2 (4%) 18 (7%) n.s.
Statins 73 (24%) 15 (33%) 58 (22%) n.s.
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Table 1(Continued )
Overall (n = 307) CKD (n = 46) Non-CKD (n = 261) p-Values
Stress ECG
Treadmill stress test 157 (51%) 12 (26%) 145 (56%) <0.001
PRP > 25,000 114 (73%) 9 (75%) 105 (72%) n.s.
Duke treadmill score 5.1± 3.4 5.5± 3.1 5.1± 3.5 n.s.
Pharmacological stress test 150 (49%) 34 (74%) 116 (44%) <0.001
Positive stress ECG 74 (24%) 5 (11%) 69 (26%) 0.026
Stress MPI
SSS 0.09± 0.39 0.20± 0.62 0.07± 0.33 0.046
SRS 0.05± 0.26 0.13± 0.40 0.04± 0.23 0.028
SDS 0.05± 0.25 0.09± 0.35 0.04± 0.23 n.s.
Mean washout rate (%) 43± 9.6 42± 10 43± 9.5 n.s.
Mean follow-up (years) 4.58± 1.51 3.88± 1.76 4.63± 1.41 0.002
Major cardiac events 9 (2.9%) 6 (13%) 3 (1.1%) <0.001
Sudden cardiac death 5 4 1
Non-fatal MI 2 1 1
Unstable angina 2 1 1
CKD, chronic kidney disease; CAD, coronary artery disease; EDD, end diastolic diameter; ESD, end systolic diameter; LVEF, left ventricular
ejection fraction; BUN, blood urea nitrogen; GFR, glomerular ﬁltration rate; CRP, C-reactive protein; HDL, high density lipoprotein; LDL,
low density lipoprotein; BNP, brain natriuretic peptide; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; ECG, electrocardiogram; PRP, pressure-rate product; MPI, myocardial perfusion images; SSS, summed stress score; SRS, summed
rest score; SDS, summed difference score; MI, myocardial infarction; n.s., not signiﬁcant.
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metes, and hypertriglyceridemia were signiﬁcantly higher
n CKD patients than in non-CKD patients. There were no
igniﬁcant differences between CKD and non-CKD patients
ith respect to hyperlipidemia, hypercholesterolemia, cere-
rovascular disease, or PAD. The frequency of smoking
istory was signiﬁcantly higher in CKD patients than in
on-CKD patients. There were no signiﬁcant differences in
requency of familial history of CAD and echocardiographic
arameters such as EDD, ESD, and LVEF between CKD and
on-CKD patients. The number of risk factors (hyperten-
ion, diabetes, hyperlipidemia, smoking, and familial history
f CAD) was signiﬁcantly higher in CKD than in non-CKD
atients. Blood concentration of hemoglobin and plasma
oncentrations of total protein, albumin, and high density
ipoprotein (HDL) and GFR were signiﬁcantly lower in CKD
han in non-CKD patients. Plasma concentrations of blood
rea nitrogen, creatinine, low density lipoprotein (LDL), and
he LDL/HDL ratio were signiﬁcantly higher in CKD than
n non-CKD patients. There were no signiﬁcant differences
etween CKD and non-CKD patients for serum concentra-
ions of C-reactive protein, HbA1c, total cholesterol, or brain
atriuretic peptide. Use of angiotensin II receptor blockers
nd beta-blockers was more frequent in CKD than non-CKD
atients.
In the stress test results, 12 CKD and 145 non-CKDatients (26% vs. 56%, p < 0.001) underwent a treadmill
tress test, and all of them achieved at least 85% of their pre-
icted heart rate. The pressure-rate product rate >25,000,
ositive stress electrocardiogram (horizontal ST segment
epression of at least 0.1mV), or duke treadmill score
m
T
t
tere not signiﬁcantly different between CKD and non-CKD
atients. No patient developed signiﬁcant chest pain dur-
ng the stress test. SSS and SRS were signiﬁcantly higher in
KD than in non-CKD patients. SDS and the mean thallium
ashout rate were not signiﬁcantly different between CKD
nd non-CKD patients.
utcomes
uring a mean follow-up period of 4.5 years, major cardiac
vents were observed in six (sudden death, 4; non-fatal MI,
; unstable angina, 1) CKD patients and three (sudden death,
; non-fatal MI, 1; unstable angina, 1) non-CKD patients.
s shown in Table 2, we assessed risk factors by univariate
ox regression hazard analysis. PAD, CKD, number of risk
actors, serum creatinine concentration, GFR, serum LDL
evel, LDL/HDL ratio, pharmacological stress test, as well
s SSS, SRS, and SDS of stress MPI were signiﬁcant risk fac-
ors. Multiple Cox regression analysis was adopted to assess
he strength of risk among these risk factors from univari-
te analysis (Table 3). Finally, only PAD, CKD, and SDS were
igniﬁcant risk factors. CKD was the strongest risk factor for
ajor cardiac events.
Fig. 3 shows Kaplan—Meier curves for freedom from
ajor cardiac events in CKD patients and non-CKD patients.
he major cardiac event rate was signiﬁcantly higher in CKD
han in non-CKD patients (1.1% vs. 13%, p < 0.001, log-rank
est).
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Table 2 Univariate Cox regression analysis.
95% CI Hazard ratio p-Values
Age 0.93—1.06 1.00 n.s.
Gender (male) 0.31—4.24 1.14 n.s.
Height 0.91—1.05 0.98 n.s.
Body weight 0.94—1.06 1.00 n.s.
Body mass index 0.87—1.23 1.03 n.s.
Past history
Hypertension 0.43—6.85 1.71 n.s.
Diabetes 0.43—6.90 1.72 n.s.
Peripheral artery disease 3.11—50.0 12.5 <0.001
Cerebral artery disease 0.72—16.7 3.47 n.s.
CKD 3.45—55.6 13.9 <0.001
Smoking 0.89—12.3 3.32 n.s.
Brinkman index 1.00—1.00 1.00 n.s.
Number of risk factors 1.21—4.64 2.37 0.012
Echocardiography
EDD 0.80—1.38 1.13 n.s.
ESD 0.72—1.25 1.07 n.s.
LVEF 0.90—1.08 0.99 n.s.
Hemoglobin 0.62—1.63 1.00 n.s.
Total protein 0.19—1.74 0.57 n.s.
Albumin 0.06—1.78 0.32 n.s.
BUN 0.99—1.05 1.02 n.s.
Creatinine 1.24—2.75 1.85 0.003
GFR 0.94—0.98 0.96 <0.001
HbA1c 0.69—1.77 1.11 n.s.
LDL 1.01—1.05 1.03 0.001
HDL 0.93—1.01 0.97 n.s.
LDL/HDL 1.41—3.88 2.34 0.001
BNP 0.99—1.01 1.00 n.s.
Pharmacological stress test 1.08—69.1 8.63 0.042
SSS 2.23—9.59 4.62 <0.001
SRS 2.39—14.3 5.84 <0.001
SDS 2.25—21.0 6.87 <0.001
CKD, chronic kidney disease; EDD, end diastolic diameter; ESD, end systolic diameter; LVEF, left ventricular ejection fraction; BUN, blood
urea nitrogen; GFR, glomerular ﬁltration rate; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein;
BNP, brain natriuretic peptide; SSS, summed stress score; SRS, summed rest score; SDS, summed difference score; n.s., not signiﬁcant.
Table 3 Multivariate Cox regression analysis.
95% CI Hazard ratio p-Values
Peripheral artery disease 1.57—47.6 8.8 0.013
CKD 2.18—76.9 13.1 0.005
SDS 1.57—24.2 6.17 0.009
SSS 0.58—11.1 2.54 n.s.
SRS 0.17—13.9 1.53 n.s.
Number of risk factors 0.59—3.08 1.35 n.s.
LDL/HDL 0.56—2.11 1.08 n.s.
Pharmacological stress test 0.31—25.1 2.81 n.s.
CKD, chronic kidney disease; HDL, high density lipoprotein; LDL, low density lipoprotein; SSS, summed stress score; SRS, summed rest
score; SDS, summed difference score; n.s., not signiﬁcant.
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Figure 3 Kaplan—Meier event-free curves for CKD and non-
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RKD patients. The major cardiac event rate was signiﬁcantly
igher in CKD patients with a rate of 13% than that in non-CKD
atients with a rate of 1.1% (p < 0.001, log-rank test).
iscussion
tress MPI has been well established for assessing the diag-
osis and prognosis of CAD [2,32—37]. In general, normal
ndings on stress MPI predict a low risk of cardiac death
nd acute coronary syndrome, with an annual event rate of
ess than 1% [1—7,32—37]. In patients with normal stress
PI, the rate of major cardiac events has been demon-
trated to be low even with a history of CAD, diabetes
ellitus, or both conditions, with an annual event rate of
ess than 1.8% [8—12]. The association between CKD and
dverse cardiovascular prognosis has been well established
rom large community-based studies [13—16]. A previous
tudy showed that even in patients with normal stress
PI (SSS < 4), the rate of cardiac death was signiﬁcantly
igher in CKD than in non-CKD patients (2.7% vs. 0.8%,
< 0.0001) [38]. However, the study included cases with
reviously known CAD. Even in normal stress MPI cases,
9% of non-CKD and 28% of CKD patients had a history of
AD. Therefore, assessing the prognosis of major cardiac
vents was important in patients with no history of CAD,
ho had normal stress MPI and CKD. In this study, CKD
as a signiﬁcant and independent risk factor for major car-
iac events. The prognosis was not good for CKD patients
3.9%/year). As shown in previous studies, proteinuria has
een a signiﬁcant risk factor for cardiovascular or total mor-
ality [39,40]. Thus, it is important to assess early stage
KD and not to allow progression of renal dysfunction. How-
ver, there were only 5 CKD patients who had preserved
FR (≥60ml/min/1.73m2) and they had no major cardiac
vents. In this study, we could not assess the prognosis of
KD patients who had preserved GFR. High incidence of
ypertension, diabetes, and smoking in the CKD group may
ffect subsequent higher major cardiac events.
imitationse analyzed a small number of CKD patients and there
ere only nine major cardiac events; we could not sepa-
ate a primary or secondary endpoint. Moreover, GFR in 46
KD patients was Stage I in 4 patients (9%), Stage II in 1T. Furuhashi et al.
atient (2%), Stage III in 29 patients (63%), Stage IV in 8
atients (17%), and Stage V in 4 patients (9%), and we could
ot assess the risk for major cardiac events with a sepa-
ate CKD grade. Only 80 patients (20 CKD and 60 non-CKD
atients) underwent electrocardiogram-gated SPECT, which
s not performed regularly at our institution, and hence, we
ould not investigate exact left ventricular systolic function.
owever, the echocardiography results indicated that all
xcept one non-CKD patient had preserved left ventricular
ystolic function.
onclusion
ormal stress MPI does not always promise a good prog-
osis for major cardiac events. Even in patients with no
istory or evidence of CAD, CKD is an independent and
igniﬁcant risk factor for major cardiac events. Patients
ith CKD and normal stress MPI may require more care-
ul and continuous follow-up for preventing major cardiac
vents.
cknowledgments
e thank Chihiro Hamazaki and Yoshiharu Ando for their
echnical assistance with stress myocardial perfusion imag-
ng. We also thank Professor Eiichi Kouda for his helpful
omments.
eferences
[1] Brown KA. Prognostic value of myocardial perfusion imag-
ing: state of the art and new developments. J Nucl Cardiol
1996;3:516—37.
[2] Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico
JA, Friedman J, Diamond GA. Incremental prognostic value
of myocardial perfusion single photon emission computed
tomography for the prediction of cardiac death: differential
stratiﬁcation for risk of cardiac death and myocardial infarc-
tion. Circulation 1998;97:535—43.
[3] Iskander S, Iskandrian AE. Risk assessment using single-photon
emission computed tomographic technetium-99m sestamibi
imaging. J Am Coll Cardiol 1998;32:57—62.
[4] Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Bur-
nette J, Krawczynska E, Cerqueira M, Maddahi J. Myoview
Multicenter Registry. Prognostic value of normal exercise and
adenosine 99mTc-tetrofosmin SPECT imaging: results from
the multicenter registry of 4,728 patients. J Nucl Med
2003;44:134—9.
[5] Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B,
Machecourt J. Long-term additive prognostic value of thallium-
201 myocardial perfusion imaging over clinical and exercise
stress test in low to intermediate risk patients: study in
1137 patients with 6-year follow-up. Circulation 1999;100:
1521—7.
[6] Underwood SR, Anagnostopoulos C, Cerqueira M, Ell PJ, Flint
EJ, Harbinson M, Kelion AD, Al-Mohammad A, Prvulovich EM,
Shaw LJ, Tweddel AC, British Cardiac Society, British Nuclear
Cardiology Society, British Nuclear Medicine Society, Royal
College of Physicians of London, et al. Myocardial perfu-
sion scintigraphy: the evidence. Eur J Nucl Med Mol Imag
2004;31:261—91.
[7] Matsuo S, Nakajima K, Horie M, Nakae I, Nishimura T, J-ACCESS
Investigators. Prognostic value of normal stress myocardial
AD
[
[
[
[
[
[
[
[
[
[
[
[
[Future cardiac events in CKD patients with no evidence of C
perfusion imaging in Japanese population. Circ J 2008;72:
611—7.
[8] Yang MF, Dou KF, Liu XJ, Yang YJ, He ZX. Prognostic value of
normal exercise 99mTc-sestamibi myocardial tomography in
patients with angiographic coronary artery disease. Nucl Med
Commun 2006;27:333—8.
[9] Abdel-Fattah A, Kamal AM, Pancholy S, Ghods M, Russell J,
Cassel D, Wasserleben V, Heo J, Iskandrian AS. Prognostic impli-
cations of normal exercise tomographic thallium images in
patients with angiographic evidence of signiﬁcant coronary
artery disease. Am J Cardiol 1994;74:769—71.
[10] Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch
R, Borges-Neto S, Berman DS, Waters DD, Heller GV. Impact
of diabetes on the risk stratiﬁcation using stress single-photon
emission computed tomography myocardial perfusion imaging
in patients with symptoms suggestive of coronary artery dis-
ease. Circulation 2002;105:32—40.
[11] Koehli M, Monbaron D, Prior JO, Calcagni ML, Fivaz-Arbane M,
Stauffer JC, Gaillard RC, Bischof Delaloye A, Ruiz J. SPECT
myocardial perfusion imaging: long-term prognostic value in
diabetic patients with and without coronary artery disease.
Nuklearmedizin 2006;45:74—81.
[12] Hachamovitch R, Hayes S, Friedman JD, Cohen I, Shaw LJ, Ger-
mano G, Berman DS. Determinants of risk and its temporal
variation in patients with normal stress myocardial perfusion
scans: what is the warranty period of a normal scan? J Am Coll
Cardiol 2003;41:1329—40.
[13] Meisinger C, Doring A, Lowel H, KORA Study Group. Chronic
kidney disease and risk of incident myocardial infarction and
all-cause and cardiovascular disease mortality in middle-aged
men and women from the general population. Eur Heart J
2006;27:1245—50.
[14] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kid-
ney disease and the risks of death, cardiovascular events, and
hospitalization. N Engl J Med 2004;351:1296—305.
[15] Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN,
Grifﬁth JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney
function as a risk factor for atherosclerotic cardiovascular out-
comes in the community. J Am Coll Cardiol 2004;41:47—55.
[16] Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Grif-
ﬁth JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease
as a risk factor for cardiovascular disease and all-cause mor-
tality: a pooled analysis of community-based studies. J Am Soc
Nephrol 2004;15:1307—15.
[17] Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L,
Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K,
Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation
between renal dysfunction and cardiovascular outcomes after
myocardial infarction. N Engl J Med 2004;351:1285—95.
[18] Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow
DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braun-
wald E, TIMI Study Group. Association of glomerular ﬁltration
rate on presentation with subsequent mortality in non-ST-
segment elevation acute coronary syndrome; observations
in 13,307 patients in ﬁve TIMI trials. Eur Heart J 2004;25:
1998—2005.
[19] Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau
JL, Moye L, Pfeffer MA, Solomon SD. Increase in creatinine and
cardiovascular risk in patients with systolic dysfunction after
myocardial infarction. J Am Soc Nephrol 2006;17:2886—91.
[20] Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO,
DiCapua P, Krumholz HM. Renal impairment and outcomes in
heart failure: systematic review and meta-analysis. J Am Coll
Cardiol 2006;47:1987—96.
[21] Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie
BM, Shlipak MG. Hemoglobin level, chronic kidney disease,
and the risks of death and hospitalization in adults with
chronic heart failure: the Anemia in Chronic Heart Failure: out-
[335
comes and Resource Utilization (ANCHOR) Study. Circulation
2006;113:2713—23.
22] Devbhandari MP, Duncan AJ, Grayson AD, Fabri BM, Keenan
DJ, Bridgewater B, Jones MT, Au J. North West Quality
Improvement Programme in Cardiac Interventions. Effect of
risk-adjusted, non-dialysis-dependent renal dysfunction on
mortality and morbidity following coronary artery bypass
surgery: a multi-centre study. Eur J Cardiothorac Surg
2006;29:964—70.
23] Cooper WA, O’Brien SM, Thourani VH, Guyton RA, Bridges CR,
Szczech LA, Petersen R, Peterson ED. Impact of renal dysfunc-
tion on outcomes of coronary artery bypass surgery: results
from the Society of Thoracic Surgeons National Adult Cardiac
Database. Circulation 2006;113:1063—70.
24] Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes
DR, Berger PB. The impact of renal insufﬁciency on clinical
outcomes in patients undergoing percutaneous coronary inter-
ventions. J Am Coll Cardiol 2002;39:1113—9.
25] Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky
AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Grifﬁn JJ, Stuckey TD,
Turco M, Carroll JD. Impact of renal insufﬁciency in patients
undergoing primary angioplasty for acute myocardial infarc-
tion. Circulation 2003;108:2769—75.
26] Ladenheim ML, Pollock BH, Rozanski A, Berman DS, Staniloff
HM, Forrester JS, Diamond GA. Extent and severity of myocar-
dial hypoperfusion as predictors of prognosis in patients
with suspected coronary artery disease. J Am Coll Cardiol
1986;7:464—71.
27] Berman DS, Abidov A, Kang X, Hayes SW, Friedman JD, Sci-
ammarella MG, Cohen I, Gerlach J, Waechter PB, Germano
G, Hachamovitch R. Prognostic validation of a 17-segment
score derived from a 20-segment score for myocardial
perfusion SPECT interpretation. J Nucl Cardiol 2004;11:
414—23.
28] Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hen-
driksen S, Kusek JW, Van Lente F, Chronic Kidney Disease
Epidemiology Collaboration. Using standardized serum creati-
nine values in the modiﬁcation of diet in renal disease study
equation for estimating glomerular ﬁltration rate. Ann Intern
Med 2006;145:247—54.
29] National Kidney Foundation. K/DOQI clinical practice guide-
lines for chronic kidney disease: evaluation, classiﬁcation, and
stratiﬁcation. Am J Kidney Dis 2002;39(2 Suppl. 1):S1—266.
30] Newman AB, Shemanski L, Manolio TA, Cushman M, Mittel-
mark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a
predictor of cardiovascular disease and mortality in the Cardio-
vascular Health Study. The Cardiovascular Health Study Group.
Arterioscler Thromb Vasc Biol 1999;19:538—45.
31] Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones
KL, Fabsitz RR, Howard BV. Relationship of high and low ankle
brachial index to all-cause and cardiovascular disease mortal-
ity: the Strong Heart Study. Circulation 2004;109:733—9.
32] Nishimura T, Nakajima K, Kusuoka H, Yamashina A, Nishimura
S. Prognostic study of risk stratiﬁcation among Japanese
patients with ischemic heart disease using gated myocardial
perfusion SPECT: J-ACCESS study. Eur J Nucl Med Mol Imag
2008;35:319—28.
33] Berman D, Hachamovitch R, Lewin H, Friedman J, Shaw L,
Germano G. Risk stratiﬁcation in coronary artery disease:
implications for stabilization and prevention. Am J Cardiol
1997;79:10—6.
34] Berman DS, Kiat H, Friedman JD, Wang FP, van Train K, Matzer
L, Maddahi J, Germano G. Separate acquisition rest thallium-
201/stress technetium-99m sestamibi dual-isotope myocardial
perfusion single-photon emission computed tomography: a
clinical validation study. J Am Coll Cardiol 1993;22:1455—64.
35] Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA,
Wang FP, Friedman JD, Germano G, Van Train K, Diamond
3[
[
[
[36
GA. Incremental value of prognostic testing in patients with
known or suspected ischemic heart disease: a basis for optimal
utilization of exercise technetium-99m sestamibi myocardial
perfusion single-photon emission computed tomography. J Am
Coll Cardiol 1995;26:639—47.
36] Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, Fried-
man J, Diamond GA. Exercise myocardial perfusion SPECT in
patients without known coronary artery disease: incremen-
tal prognostic value and use in risk stratiﬁcation. Circulation
1996;93:905—14.
37] Galassi AR, Azzarelli S, Tomaselli A, Giosofatto R, Ragusa A,
Musumeci S, Tamburino C, Giuffrida G. Incremental prognos-
tic value of technetium-99m-tetrofosmin exercise myocardial
perfusion imaging for predicting outcomes in patients with
[T. Furuhashi et al.
suspected or known coronary artery disease. Am J Cardiol
2001;88:101—6.
38] Hakeem A, Bhatti S, Dillie KS, Cook JR, Samad Z, Roth-
Cline MD, Chang SM. Predictive value of myocardial perfusion
single-photon emission computed tomography and the impact
of renal function on cardiac death. Circulation 2008;118:
2540—9.
39] Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Protein-
uria as a risk factor for cardiovascular disease and mortality in
older people: a prospective study. Am J Med 2000;109:1—8.
40] Grimm Jr RH, Svendsen KH, Kasiske B, Keane WF, Wahi MM.
Proteinuria is a risk factor for mortality over 10 years of follow-
up. MRFIT Research Group. Multiple Risk Factor Intervention
Trial. Kidney Int 1997;52(Suppl. 63):S10—4.
